DB05413InvestigationalProtein Based Therapies
Tifuvirtide is the first members of a new class of anti-HIV drugs which is also called fusion inhibitors. It has received fast-track designation from the FDA and is in Phase...
- Mechanism
- Curator reviewed
Tifuvirtide binds to a slightly different region of the HIV virus than Fuzeon (enfuvirtide). As a result,it exhibits activity against Fuzeon-resistant viruses. Tifuvirtide is designed to block fusion of HIV with host cells before the virus enters the cell and begins its replication process.
- Primary indication
- Investigated for use/treatment in acquired immune deficiency syndrome (AIDS) and aids-related infections and HIV infection.Curator reviewed
- Also known as
- Peptide T1249
- Code names
- T-1249
Resolves to
Targets
What you can answer from here — as of August 26, 2022
1Protein targetEach mapped to UniProt, with action and pharmacological actionListed above
Which drugs share a target with Tifuvirtide, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account